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Experimental evidence suggests that ageing-associated alterations in the tissue microenvironment act to promote prostate
carcinogenesis. In this review, we survey the cellular state of senescence, review its causes, and describe associations with ageing and
cancer. We further discuss senescent stromal gene expression changes, which may mediate these effects, and that may serve as
therapeutic targets.
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In the United States and United Kingdom, prostate cancer is the
most common non-cutaneous malignancy and the second leading
cause of cancer deaths in men. In 2007, it is estimated that upwards
of 200000 and 30000 new cases of prostate cancer will be
diagnosed in the United States and United Kingdom, respectively,
with more than 27000 deaths predicted to be attributable to this
disease in the United States alone (Office of National Statistics,
2006; Jemal et al, 2007). As men age, the risk of clinically detected
prostate cancer increases dramatically from 0.01% for men aged
less than 40 to about 14% for men aged 70 and older for a
cumulative lifetime risk of 17% (Jemal et al, 2007). Autopsy studies
designed to assess subclinical disease in different age cohorts
report substantially higher rates of cancer incidence that parallel
the age-associated increases in clinical diagnoses. For example,
27% of men aged 30–39 and 34% of men aged 40–49 harbour foci
of adenocarcinoma in the prostate (Sakr et al, 1993). In fact,
advancing age is consistently the greatest risk factor for the
development of prostate cancer across racial and ethnic groups.
Historically, the relationship between ageing and carcinogenesis
has been attributed to somatic mutations that accumulate in the
epithelium over time due to oxidative damage to DNA nucleotide
structure and due to failures of DNA damage repair systems. At the
cellular level, increasing dysfunction with cumulative damage
results in one of the following several cellular responses: cell-cycle
arrest and injury repair, apoptosis, mitotic catastrophe, cellular
senescence, or neoplastic transformation (Roninson, 2003).
However, in addition to the epithelium, ageing-related cellular
changes also impact the other tissue compartments that include
extracellular matrix, infiltrating inflammatory cells, and consti-
tuent mesenchymal cell types such as fibroblasts and smooth
muscle. Importantly, the microenvironment is increasingly
recognised as an important contributor to the development of
epithelial cancers (Krtolica et al, 2001; te Poele et al, 2002; Cunha
et al, 2003) (Figure 1). In this context, the summation of cellular
responses to the cumulative effects of metabolic stress and damage
responses that occur during normal or accelerated ageing
processes alters the microenvironment of the organ, and may
contribute to the increased risk of carcinoma with advancing age.
This review will discuss several lines of experimental evidence
implicating ageing-related changes in fibroblast constituents of the
prostate microenvironment as direct contributors to the process of
carcinogenesis.
CELLULAR SENESCENCE AND AGEING
The term senescence is derived from the Latin word senex, meaning
old man or old age. The concept of organismal senescence is used
to generally describe the chronological ageing of whole organisms
and ageing is commonly used interchangeably with senescence.
The concept of cellular senescence is defined more precisely due to
an improved understanding of the molecular events involved in
this process. Cellular senescence was first associated with the
replicative exhaustion, where normal diploid differentiated cells
lose the ability to divide and enter a state of permanent growth
arrest in the G1/G0 cell-cycle phase (Dimri et al, 1995; Roninson,
2003; Zhang, 2007). Importantly, senescent cells are not inert, as
they remain metabolically active and are resistant to apoptosis,
though they do not respond to mitogens. Upon becoming
senescent, cells exhibit a classic morphology including enlarge-
ment with splaying and increased granularity. Classically identified
in cell culture systems upon serial passage, replicative senescence
has subsequently been attributed to telomere shortening. The
cellular programme of senescence is subsequently activated by
sensing of the altered telomeric structure. Activation of p53 and
p21 has been implicated in the cell-cycle arrest of senescence.
Additionally, inactivation of pRB and activation of p16 can also
prevent cell-cycle progression (Roninson, 2003; Zhang, 2007)
(Figure 1).
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of cellular damage, including (a) cell stress (such as oxidative
stress); (b) DNA damage; and (c) oncogene activation (e.g., K-ras,
BRAF). Examples of DNA damage that induce senescence include
chemotherapy and ionizing radiation. Interestingly, although the
cell-cycle consequences of senescence are universal, the mecha-
nisms that underlie the state of growth arrest and the gene
expression programmes reflecting these varied mechanisms
exhibit substantial differences (Zhang, 2007). Paradoxically,
although it is thought that the cellular senescence programme
may have developed as a mechanism to prevent malignant
transformation by preventing continued replication in the setting
of carcinogenic events (Roninson, 2003; Parrinello et al, 2005),
accumulating data suggest that over time, residual senescent cells
may alter the microenvironment to promote carcinogenesis in
remaining non-senescent epithelium. This scenario has been
suggested to represent an example of evolutionary antagonistic
pleiotropy whereby natural selection would retain a mechanism
(senescence) that protected the organism from a detrimental event
(carcinogenesis), but this selected mechanism could have adverse
consequences after selective pressures were no longer operative
(Krtolica et al, 2001). In this example, senescence would be under
strong positive selection during the reproductive phase of the life
cycle, but pressures to avoid detrimental effects of senescence after
reproductive years would not be propagated. As resident members
of the prostate microenvironment, senescent epithelial or stromal
cells (e.g. fibroblasts) could both contribute detrimental influences
on neighbouring proliferating epithelium.
Consistent with the expectation of age-associated accrual
of cellular damage, senescent cells accumulate with ageing.
Senescence-associated b-galactosidase (SA-b-Gal), a metabolic
marker primarily associated with senescence in vitro, has been
used to identify increased numbers of senescent cells in aged
human liver (Paradis et al, 2001) and skin (Dimri et al, 1995)
compared to young tissues. Recently, other markers such as p16,
g-H2AX, and 53BP1 that are associated with in vitro senescence
have been shown to accumulate with advancing age in a number of
organisms that include mice (Krishnamurthy et al, 2004), primates
(Herbig et al, 2006), and humans (Melk et al, 2004). These studies
have provided clear molecular evidence that cells rendered
senescent by ageing, stress, or oncogenesis accumulate over time.
DIFFERENTIAL CONSEQUENCES OF SENESCENCE
The induction of senescence in the epithelium of tissues and
organs such as the prostate gland is believed to have evolved as an
intrinsic tumour suppressive mechanism in proliferative cells that
accumulate DNA lesions potentially leading to neoplasia if not
restrained. In a mouse model of prostate cancer, inhibition of
Pten-associated carcinogenesis required functional p53 that
operated, in part, through induction of senescence in the prostate
epithelium (Chen et al, 2005). Analyses of human prostate cancer
tissue supported this model, as senescent cells were identified in
areas of benign prostatic hyperplasia and prostatic intraepithelial
neoplasia (PIN), but were not observed within invasive neoplasms
(Chen et al, 2005). Similarly, senescent cells have been shown to be
relatively abundant in benign human nevi expressing the
BRAF(V600E) oncogene (Michaloglou et al, 2005). These pre-
neoplastic lesions are stable for decades before progressing to
melanoma, at which point, senescent cells are infrequent. Mouse
models of skin cancer, pancreatic cancer, and lung cancer have
also been shown to contain senescent cells in preneoplastic lesions,
but not in invasive cancers (Collado et al, 2005). These data
indicate that a prerequisite for invasive neoplasia involves
circumventing the growth-suppressing pathways that comprise
the senescence programme. Interestingly, in a mouse model of
oncogene-induced lymphoma, tumours capable of undergoing
cellular senescence had a significantly better response to
chemotherapy than tumours, which were not capable of
senescence (Schmitt et al, 2002). However, these mice eventually
succumbed to their lymphomas, demonstrating the limitations of
the tumour-suppressive effects of the senescence pathway. In vitro,
cancer cells that have undergone chemotherapy-induced senescence
are (infrequently) able to resume proliferation (Roberson et al,
2005). This may suggest that senescent cancer cells might represent
a potential reservoir for resistance and relapse to conventional
medical therapies.
In contrast to the tumour-suppressing effects of the senescence
programme operating within the individual cells harbouring
oncogenic alterations as described above, senescent cells, particu-
larly of the fibroblastic stromal compartment, may provide signals
to neighbouring cells that promote carcinogenesis and tumour
progression. For example, senescent but not pre-senescent breast
fibroblasts were shown to transform immortal, non-neoplastic
breast epithelial cell lines in a mouse xenograft model and to
promote progression of neoplastic cell lines (Krtolica et al, 2001).
Senescent fibroblasts also inhibited the normal differentiation
programme of mammary gland development (Parrinello et al,
2005). Bavik et al (2006) extended these observations made in
breast cancer to studies of prostate cancer and demonstrated that
senescent prostate fibroblasts can stimulate the growth of pre-
neoplastic and neoplastic prostate epithelium in vitro.A n
important study demonstrating the potential in vivo relevance
of these observations focused on the localised regions directly
surrounding human ovarian cancers. Increased numbers of
senescent stromal cells were enriched in regions juxtaposed to
cancer epithelium, a finding that indicates an intimate relationship
between the influences and interactions of tumour cells and their
attendant microenvironment (Yang et al, 2006).
THE PROSTATE MICROENVIRONMENT AND
PROSTATE CARCINOGENESIS
The microenvironment of the prostate gland consists of several
distinct cellular components, including epithelium, smooth
muscle, fibroblasts, vascular structures, extravasated blood cells,
as well as insoluble matrix and circulating soluble factors, all
interacting in the context of an extracellular matrix. Although
mutations have historically been viewed as the sine qua non of























Figure 1 Ageing, senescence, and cellular phenotypic responses. With
chronological ageing, telomere attrition leading to replicative exhaustion
and/or an accumulation of environmental exposures leads to cellular
senescence. DNA damage is sensed by the cell resulting in the activation of
the p53–p21 and/or pRB–p16 pathways, leading to induction and
maintenance of the senescent cellular state. The senescence programme
consists of the robust expression of a diverse set of genes, a subset of
which have the potential to alter the tissue microenvironment and
promote carcinogenesis.
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ment have the potential to contribute to the development and
progression of invasive epithelial cancers (Figure 2). An example
of this process was definitively shown in a mouse model, whereby
alterations in TGF-b signalling in stromal fibroblasts produced
forestomach neoplasms and PIN (Bhowmick et al, 2004).
The stroma of the prostate has been established to be an
important regulator of proper gland morphogenesis and mature
function. For example, recombination studies with mouse
embryonic tissues have demonstrated that early androgen signal-
ling occurs through the stromal compartment. This interaction was
established through elegant experiments where AR-defective Tfm
stromal tissues were not able to mediate prostatic epithelial
development, while AR-defective epithelium combined with
mesenchyme expressing a wild-type AR proceeded to develop
normally (Cunha et al, 2003). In addition to the influence of
stroma on developmental processes, the role of stromal cell
phenotypes in prostate carcinogenesis has been investigated by
several groups. Rowley and co-workers (Tuxhorn et al, 2002),
determined that a reactive stroma exhibiting features associated
with wound healing is capable of stimulating prostate epithelial
proliferation in vivo. Many of these reactive characteristics have
been observed in stroma directly associated with human cancers.
Prostate fibroblasts derived from regions harbouring invasive
cancer, termed cancer-associated fibroblasts, but not fibroblasts
adjacent to normal epithelium, termed normal-associated fibro-
blasts, can promote the invasive phenotype of initiated prostate
epithelial cells (Cunha et al, 2003). Finally, embryonal
prostate stroma (urogenital mesenchyme), genetically pro-
grammed through exposure to testosterone and estradiol, is
capable of promoting tumour development from immortal, but
non-neoplastic prostate epithelium (Cunha et al, 2003). Thus, a
neoplastic environment is capable of imparting a sustained cancer-
promoting phenotype within cells comprising the peri-tumoural
stroma. Senescent stromal cells may contribute to these tumour-
promoting events. Currently, the identification and modulation of
effector proteins derived from reactive and senescent stromal
phenotypes is an active area of investigation.
MEDIATORS OF EPITHELIAL CARCINOGENESIS IN
THE AGED OR SENESCENT MICROENVIRONMENT
The demonstration that senescent cells accumulate in stromal
compartments of aged individuals, coupled with experiments
establishing the ability of senescent fibroblasts to profoundly alter
the growth characteristics of epithelial cells, has led to efforts
designed to define the specific molecular mechanisms by which
this process occurs. Stroma-derived factors with the potential to
influence epithelial phenotypes include cell surface molecules,
secreted soluble factors, and secreted extracellular matrix proteins.
To identify senescence- or ageing-associated changes in such
factors, several groups have employed global profiling strategies in
relatively unbiased searches. In a study reported by Begley et al
(2005), microarrays were used to identify transcript alterations
that specifically associated with differences in the age of cells
comprising human prostate stroma. Primary fibroblast cultures
were established from prostates resected from men aged 40, 40, 51,
52, 64, and 71 years. Differences in gene expression between
younger men (aged 40–52) and older men (64–70) were
compared to identify ageing-associated gene expression changes.
Functionally, the stroma derived from older donors were found to
be more permissive for the growth of the initiated, pre-neoplastic
prostate epithelial cell line N15C6. Fifty-four unique transcripts
were found to be differentially expressed with ageing, of which 41
were upregulated and 13 were downregulated. Of the upregulated
transcripts, nine encoded secreted proteins. CXCL12 (SDF-1) was
the most highly upregulated gene. Subsequent experiments
confirmed age-associated increases in mRNA and protein secre-
tion levels, as well as the contribution of increased CXCL12
signalling to increased epithelial proliferation (Begley et al, 2005).
Bavik et al (2006) reported the use of microarray profiling to
identify transcript alterations in prostate fibroblasts that asso-
ciated with the induction of senescence (Table 1). A comparison
of three different senescence data sets identified 710 genes with
consistent and significant alterations in gene expression of X2-
fold. Of these, 407 had increased expression levels with senescence
and 303 were decreased. Seventy-one of the upregulated genes
exhibited features of extracellular proteins as identified by Genome
Ontology annotations. Consistent with the prostate fibroblast
ageing data set, CXCL12 was one of the significantly upregulated
genes with senescence. Co-cultures of prostate epithelium with
senescent fibroblasts produced significantly higher epithelial cell
proliferation rates when compared with pre-senescent fibroblasts.
Conditioned medium from the senescent fibroblasts recapitulated
these findings, indicating that a large component of the growth-
promoting effect was due to paracrine-acting factors. Further work
designed to identify individual genes contributing to the paracrine
effects determined that fibroblast-derived amphiregulin directly
contributed to the senescence-associated proliferative effects on
prostate epithelium (Bavik et al, 2006).
Global studies of the prostate fibroblast senescence programme
determined that specific categories of biological processes such as
cell communication, extracellular matrix structural constituents,
immune and inflammatory responses, and insulin-like growth
factor binding were highly enriched. Many upregulated genes
within these diverse functional categories could contribute to the
effects of stromal senescence on epithelial cell behaviour. One set
















Figure 2 The prostate microenvironment and influence of senescence
on carcinogenesis. (A) The normal microenvironment involves reciprocal
paracrine interactions between epithelium and constituents of the stroma
(fibroblasts, smooth muscle, endothelium, matrix, and inflammatory cells
(not shown)) that serve to maintain homoeostasis and a functional
differentiated tissue state. Microenvironmental signalling maintains tissue
homoeostasis. (B) Cellular damage in the context of chronological ageing
and/or oxidative stress leads to the accumulation of senescent stromal cells,
which produce paracrine-acting factors capable of inducing or promoting
epithelial carcinogenesis. (C) Continued promotion of carcinogenesis by
the altered microenvironment, including changes in the matrix components,
contributes to invasive and metastatic epithelial cell phenotypes. Aberrant
paracrine signals from initiated epithelial cells also contribute to further
stromal senescence and/or the development of a reactive stroma that
further influences carcinogenesis.
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morphogenic protein 1, macrophage-inhibitory cytokine 1 (MIC-1/
PLAB/GDF15), connective tissue growth factor, and vascular
endothelial growth factor (VEGF). The insulin-like growth factor
binding proteins were also significantly altered by senescence,
including IGFBP2, IGFBP3, IGFBP5, and IGFBP6. These proteins
may directly signal through prostate epithelial surface receptors, or
may also signal through crosstalk to the androgen pathway, which
is central to prostate carcinogenesis (Culig et al, 1994). It is well-
established that VEGF expression is important in angiogenesis, an
essential prerequisite for tumour growth beyond hypoxia-limiting
sizes (Hrouda et al, 2003). Vascular endothelial growth factor also
serves as a chemo attractant for tumour-associated macrophages,
which further promote tumorigenesis and progression (Lewis and
Pollard, 2006).
A second category of genes upregulated in senescent fibroblasts
includes chemokines and cytokines; CXCL12, CXCL1, CCL11,
CCL13, CCL20, C17, IL6, and IL8. As with the growth factors, these
proteins, CXCL12, CXCL1, IL6, and IL8 in particular, have
previously been shown to stimulate the growth, survival, or
invasive behaviour of prostate epithelium (Engl et al, 2006). In
addition, the cytokines IL8 and C17 are angiogenic (Hrouda et al,
2003). It has been increasingly recognised that inflammation in
general, and macrophages in particular, may play significant roles
in prostate carcinogenesis and cancer progression. Chemokines
secreted by senescent stroma such as CXCL1 and IL8 may attract
macrophages, and subsequently modulate their function; for
example, converting anti-infectious M1 into the pro-carcinogenic
M2 phenotype (Mantovani et al, 2004). M2 macrophages have been
shown to secrete their own array of signalling molecules, which
directly stimulate the epithelium, cause further inflammatory
stimulation, and promote angiogenesis (Mantovani et al, 2006).
M2 macrophages also have a diminished capacity for antigen
presentation, which would promote the survival of neoplastic
clones (Mantovani et al, 2004).
The third set of upregulated genes in senescent stroma with the
potential to modulate prostate carcinogenesis include extracellular
matrix proteins, proteases, and protease inhibitors, which can
serve to modify paracrine-acting proteins and remodel structural
components of the microenvironment. Upregulated extracellular
matrix proteins include collagen Ia2, collagen IIIa1, collagen IVa5,
collagen VIa1, collagen VIa2, collagen VIIa1, collagen XVa1,
laminin a4, laminin b2, integrin a5, integrin b1, integrin b4,
osteonectin (SPARC), osteocalcin, osteopontin, syndecan 2, and
fibronectin 1. Collagen IV is known to be upregulated in the
neu-transformed, tumorigenic PC3 prostate cancer cell line, and
osteopontin and osteocalcin are upregulated as LNCaP cells
progress to the more aggressive C4-2 cell line (Stewart et al,
2004). Extracellular matrix-modifying proteinases and proteinase
inhibitors upregulated with senescence include ADAMTS1, MMP2,
MMP3, MMP9, cathepsin D, cathepsin O, cystatin S, cystatin B,
cystatin C, TIMP1, and TIMP2. Matrix metalloproteinases can
function to degrade the stroma and basement membrane, and
aspects of invasive, and metastatic features of prostate cancers
appear to be dependent on the ratios of MMP2, MMP9, and TIMP1
(Stewart et al, 2004). As many signalling molecules directly
associate with components of the extracellular matrix, MMP-
mediated alterations in the structural constituents of the micro-
environment might affect the binding and availability of these
factors. Matrix metalloproteinases also act to directly process
growth factors, growth factor receptors, cytokines, chemokines,
and other precursor proteins. Together, the sheer number of
changes in the expression of microenvironment constituents that
associate with the senescence gene expression programme
provides challenges in determining which alteration represent
the dominant influences on adjacent cell types (Figure 2).
However, establishing the key nodes that dictate stromal effects
on cellular characteristics such as proliferation, resistance to cell
death, and invasive capacity, would serve to prioritise methods for
interfering with detrimental signals.
CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS
FOR INVESTIGATION
Current research focuses on identifying factors that underlie the
profound age-associated increases in prostate cancer incidence.
Clinically, the diagnosis and treatment of prostate cancer could be
impacted at several levels. First, the identification of individual or
patterns of secreted factors might provide biomarkers for early
detection of prostate cancers, or more importantly, those cancers
with the propensity for lethal behaviour. While prostate-specific
antigen has been widely used as a screening test, its use and
application continues to be controversial in many circles due to its
lack of specificity and sensitivity. Novel patterns of secreted
proteins identified through studies of ageing may provide
diagnostic tools with the potential enhanced sensitivity by focusing
on high-risk populations. In this context, it is important to
recognise that molecular ageing may be distinct from chronolo-
gical ageing, and senescence changes in the tumour micro-
environment may reflect a particular sensitivity to DNA damaging
agents or exposure to chronic inflammatory insults.
Second, prostate cancer has a significant lag time between the
age at which cancers can be histologically detected with high
prevalence and the age at which most clinical diagnoses are made.
For example, pre-neoplastic PIN lesions can be identified in a
substantial number (9%) of men aged 20–29, and asymptomatic
histologic cancers and PIN lesions are reported to be present in 27
and 20% of men aged 30–39, respectively (Sakr et al, 1993). By
contrast, only 0.01% of men aged less than 40 will be clinically
diagnosed with prostate cancer (Jemal et al, 2007). Chemo-
preventive agents, potentially targeting cancer-promoting stromal
Table 1 A concise sampling of genes with altered expression in senescence
Gene Gene name Fold increase in senescence Reference for effects in prostate cancer
CXCL12 Stromal cell-derived factor 1 3.39 Engl et al, 2006
VEGF Vascular endothelial growth factor 1.44 Hrouda et al, 2003; Lewis and Pollard, 2006
CXCL1 Melanoma growth stimulating activity a 3.55 Engl et al, 2006; Mantovani et al, 2004
IL6 Interleukin 6 2.31 Engl et al, 2006
IL8 Interleukin 8 6.76 Hrouda et al, 2003; Mantovani et al, 2004; Engl et al, 2006
COL4A5 Collagen 4 a 5 2.34 Stewart et al, 2004
SPARC Osteonectin 1.92 Stewart et al, 2004
SPP1 Osteopontin 1.20 Stewart et al, 2004
MMP2 Matrix metalloproteinase 2 4.33 Stewart et al, 2004
MMP9 Matrix metalloproteinase 9 1.12 Stewart et al, 2004
TIMP1 Tissue inhibitor of metallopeptidase 1 2.65 Stewart et al, 2004
AREG Amphiregulin 4.4 Bavik et al, 2006
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times between PIN, cancer development, and/or progression to
clinically-relevant disease, could delay or reverse the progression
of prostate cancer.
Third, prostate cancer therapy may be improved by broadening
the diversity of targets. In particular, directing treatment towards
mechanisms modulating resistance to cytotoxic chemotherapy, or
influencing components of the tumour microenvironment could
offer novel combinations that may serve to abort resistance
mechanisms and mitigate toxicities. For example, it is now
possible to directly inhibit angiogenesis in the tumour micro-
environment through approaches that modulate the effects of
VEGF, a growth factor shown to be upregulated by senescent
fibroblasts. Other agents such as COX-2 inhibitors may serve to
influence effectors of the inflammatory or wound responses
that exert growth or survival effects towards tumour cells. In
prostate cancer, these efforts are not mature to date. However,
improvements in our understanding of the biology of ageing and
senescence should provide mechanistic insights into the relation-
ship between these processes and neoplastic growth, and allow
focused efforts to develop tools for the optimised preventive,
diagnostic, and treatment strategies.
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